key: cord-1047584-mtwoc8eh authors: Zhao, Xin; Zheng, Anqi; Li, Dedong; Zhang, Rong; Sun, Huan; Wang, Qihui; Gao, George F; Han, Pengcheng; Dai, Lianpan title: Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants date: 2021-08-20 journal: Lancet Microbe DOI: 10.1016/s2666-5247(21)00217-2 sha: bc75ebc2924b3c3c51b375e214268199b6ee4833 doc_id: 1047584 cord_uid: mtwoc8eh nan The 28 serum samples were collected from vaccine recipients after 3 doses of 25 μg ZF2001 vaccine on 0, 1, 2 Months (16 vaccinees) or 0, 1, (4-6) Months (12 vaccinees) 1,2 . The participants including 13 males and 15 females. Detailed information was provide in Table S1 . All candidates signed the written informed consent. The construction of VSV-ΔG-GFP based SARS-CoV-2 pseudotyped virus was The TU numbers were calculated after a 15 h incubation on a CQ1 confocal image cytometer (Yokogawa) 3 . The TU numbers were calculated by CQ1 software and statistical analyses were performed by GraphPad Prism 8.0 (GraphPad Software Inc.) for all experiments. pVNT50 titers were determined by non-linear regression (Fig. S2 ). pVNT50 below the lower limit of detection (<20) were recorded as 10 in the geometric mean calculation. Neutralization values between different strains were compared using a two-tailed Wilcoxon matched-pairs signed-rank test. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials Viral targets for vaccines against COVID-19 Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE-2 in humans and other species The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity The molecular basis for SARS-CoV-2 binding to dog ACE2 Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerging microbes & infections 2020 SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies Transmission dynamics of an outbreak of the COVID-19 Delta variant B.1.617.2 -Guangdong Province, China Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. The New England journal of medicine 2021 SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv : the preprint server for health sciences SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness